• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Ann Rheum Dis. Dec 2005; 64(12): 1731–1736.
Published online May 5, 2005. doi:  10.1136/ard.2005.035691
PMCID: PMC1755298

Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis

Abstract

Background: Early treatment prevents progression of joint damage in rheumatoid arthritis (RA), but diagnosis in early disease is impeded by lack of appropriate diagnostic criteria.

Objective: To study the value of rheumatoid factor (RF), anti-cyclic citrullinated peptide autoantibodies (anti-CCP), and anti-RA33 autoantibodies for diagnosis of RA and prediction of outcome in patients with very early arthritis.

Methods: The prospective follow up inception cohort included 200 patients with very early (<3 months) inflammatory joint disease. Autoantibodies were measured at baseline and analysed in a tree based model which aimed at determining the added diagnostic value of testing for anti-CCP and anti-RA33 as compared with RF alone.

Results: RA was diagnosed in 102 patients, while 98 developed other inflammatory arthropathies. Receiver operator curve analysis showed an optimum cut off level for RF at 50 U/ml, above which anti-CCP and anti-RA33 had no additional diagnostic value. Remarkably, RF [gt-or-equal, slanted]50 U/ml and anti-CCP showed similar sensitivity and high specificity for RA, but overlapped considerably. Anti-RA33 was less specific and did not correlate with RF or anti-CCP. Among patients with RA, 72% showed at least one of these three autoantibodies, compared with 15% of non-RA patients. RF [gt-or-equal, slanted]50 U/ml and anti-CCP were predictors of erosive disease, whereas anti-RA33 was associated with mild disease.

Conclusions: Stepwise autoantibody testing in early inflammatory joint disease, starting with RF, followed by anti-CCP (in patients with RF <50 U/ml), and finally anti-RA33, should be used as a sensitive and effective strategy for distinguishing patients with RA at high risk for poor outcome.

Full Text

The Full Text of this article is available as a PDF (92K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • O'Dell James R. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2591–2602. [PubMed]
  • Smolen Josef S, Aletaha Daniel, Machold Klaus P. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005 Feb;19(1):163–177. [PubMed]
  • Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S154–S157. [PubMed]
  • van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, van Albada-Kuipers GA, ter Borg EJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996 Apr 15;124(8):699–707. [PubMed]
  • Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999 May 8;353(9164):1568–1573. [PubMed]
  • van Aken J, Lard LR, le Cessie S, Hazes JMW, Breedveld FC, Huizinga TWJ. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2004 Mar;63(3):274–279. [PMC free article] [PubMed]
  • Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004 Jul;43(7):906–914. [PubMed]
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. [PubMed]
  • Symmons Deborah P M, Hazes Johanna M W, Silman Alan J. Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. J Rheumatol. 2003 May;30(5):902–904. [PubMed]
  • Machold Klaus P, Stamm Tanja A, Eberl Gabriele J M, Nell Valerie K P, Dunky Attila, Uffmann Martin, Smolen Josef S. Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol. 2002 Nov;29(11):2278–2287. [PubMed]
  • Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987 May 16;1(8542):1108–1111. [PubMed]
  • Sinclair David, Hull Richard G. Why do general practitioners request rheumatoid factor? A study of symptoms, requesting patterns and patient outcome. Ann Clin Biochem. 2003 Mar;40(Pt 2):131–137. [PubMed]
  • Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998 Jan 1;101(1):273–281. [PMC free article] [PubMed]
  • Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, Serre G. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995 Jun;95(6):2672–2679. [PMC free article] [PubMed]
  • Vossenaar Erik R, Després Normand, Lapointe Elvy, van der Heijden Annemarie, Lora Maximillian, Senshu Tatsuo, van Venrooij Walther J, Ménard Henri A. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6(2):R142–R150. [PMC free article] [PubMed]
  • Steiner Günter, Smolen Josef. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 2002;4 (Suppl 2):S1–S5. [PMC free article] [PubMed]
  • Aho K, Steiner G, Kurki P, Paimela L, Leirisalo-Repo M, Palosuo T, Smolen JS. Anti-RA 33 as a marker antibody of rheumatoid arthritis in a Finnish population. Clin Exp Rheumatol. 1993 Nov-Dec;11(6):645–647. [PubMed]
  • Aho K, von Essen R, Kurki P, Palosuo T, Heliövaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol. 1993 Aug;20(8):1278–1281. [PubMed]
  • Rantapä-Dahlqvist Solbritt, de Jong Ben A W, Berglin Ewa, Hallmans Göran, Wadell Göran, Stenlund Hans, Sundin Ulf, van Venrooij Walther J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003 Oct;48(10):2741–2749. [PubMed]
  • Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004 Sep;63(9):1090–1095. [PMC free article] [PubMed]
  • Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004 Sep;63(9):1085–1089. [PMC free article] [PubMed]
  • Söderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol. 2004;33(3):185–188. [PubMed]
  • Raza Karim, Breese Mike, Nightingale Peter, Kumar Kanta, Potter Tanya, Carruthers David M, Situnayake Deva, Gordon Caroline, Buckley Christopher D, Salmon Mike, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol. 2005 Feb;32(2):231–238. [PMC free article] [PubMed]
  • van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes REM, Huizinga TWJ. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004 Mar;50(3):709–715. [PubMed]
  • Nielen MMJ, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BAC, Hamann D. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis. 2005 Aug;64(8):1199–1204. [PMC free article] [PubMed]
  • Meyer O, Labarre C, Dougados M, Goupille Ph, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003 Feb;62(2):120–126. [PMC free article] [PubMed]
  • Jansen Annemarie L M A, van der Horst-Bruinsma Irene, van Schaardenburg Dirkjan, van de Stadt Rob J, de Koning Margret H M T, Dijkmans Ben A C. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol. 2002 Oct;29(10):2074–2076. [PubMed]
  • Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS. Early arthritis therapy: rationale and current approach. J Rheumatol Suppl. 1998 Jul;53:13–19. [PubMed]
  • Machold KP, Nell VP, Stamm TA, Eberl G, Steiner G, Smolen JS. The Austrian Early Arthritis Registry. Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S113–S117. [PubMed]
  • Harrison BJ, Symmons DP, Barrett EM, Silman AJ. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol. 1998 Dec;25(12):2324–2330. [PubMed]
  • Aletaha D, Eberl G, Nell VPK, Machold KP, Smolen JS. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis. 2002 Jul;61(7):630–634. [PMC free article] [PubMed]
  • Green M, Marzo-Ortega H, McGonagle D, Wakefield R, Proudman S, Conaghan P, Gooi J, Emery P. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum. 1999 Oct;42(10):2184–2188. [PubMed]
  • Fritsch Ruth, Eselböck Daniela, Skriner Karl, Jahn-Schmid Beatrice, Scheinecker Clemens, Bohle Barbara, Tohidast-Akrad Makiyeh, Hayer Silvia, Neumüller Josef, Pinol-Roma Serafin, et al. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol. 2002 Jul 15;169(2):1068–1076. [PubMed]
  • Skriner K, Sommergruber WH, Tremmel V, Fischer I, Barta A, Smolen JS, Steiner G. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J Clin Invest. 1997 Jul 1;100(1):127–135. [PMC free article] [PubMed]
  • Smolen JS. The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT) Br J Rheumatol. 1992 Apr;31(4):219–220. [PubMed]
  • Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977 Jul;18(4):481–491. [PubMed]
  • Kirwan JR. Using the Larsen index to assess radiographic progression in rheumatoid arthritis. J Rheumatol. 2000 Jan;27(1):264–268. [PubMed]
  • Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561–577. [PubMed]
  • Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990 Jan 27;300(6719):230–235. [PMC free article] [PubMed]
  • Grigor Catriona, Capell Hilary, Stirling Anne, McMahon Alex D, Lock Peter, Vallance Ramsay, Kincaid Wilma, Porter Duncan. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17;364(9430):263–269. [PubMed]

Figures and Tables

Figure 1
 ROC curve for the tree based model. Using a computer based tree model we obtained the optimum cut off value for RF above which determining anti-CCP and/or anti-RA33 would add no significant benefit in identifying patients with RA. This value ...
Figure 2
 High titre RF and anti-CCP are associated with rapid radiographic progression of RA. Box plots showing the difference in Larsen scores (grade 1 abandoned) in (A) patients with RA with high titre RF v low titre or negative RF; (B) patients with ...
Figure 3
 Prognostic value of autoantibodies for predicting improvement of disease activity. Baseline disease activity (DAS28) was similar in all patient groups (dark grey columns). At the study end point, DAS28 (light grey columns) was significantly ...
Figure 4
 Decision tree to determine risk of RA and erosive disease in patients with early arthritis. All patients with early arthritis are tested for RF. High titre RF ([gt-or-equal, slanted]50 U/ml) is highly predictive for the diagnosis of RA and for developing ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...